Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uPAR-PET/CT in Radium-223 treatment of metastatic castration-resistant prostate cancer
2016-002184-34Phase 2Terminated
- Sponsor
- Rigshospitalet
- Start
- Aug 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Rigshospitalet. Primary endpoint: Change in 68Ga-NOTA-AE105 uptake (SUVmax and SUVmean). Started Aug 2016; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-002184-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002184-34.